Evotec Investor Day Presentation Deck

evotec A novel biologic to cure HBV EVT895: HBV infections are a major global health burden >900,000 deaths in 2015 • HBV kills as many people world-wide as HIV Current therapeutics have a low cure rate • Some being poorly tolerated Though a safe and effective vaccine is available, it is not used in all countries • It will be decades before impact is seen on global disease burden PAGE 31 HBV cure is WHO target for 2030 agenda for sustainable development Viral Hepatitis B in the world 7m AMERICAS 257 m GLOBAL 15 m EUROPE 60 m AFRICA SANOFI 21 m EASTERN MEDITERRANEAN 39 m SOUT-EAST ASIA World Health Organization 115 m WESTERN PACIFIC

View entire presentation